Anzeige
30.12.2024 | original report
CRLF2 expression associated with poor outcome in Philadelphia-negative acute lymphoblastic leukemia
Erschienen in: memo - Magazine of European Medical Oncology
Einloggen, um Zugang zu erhaltenSummary
Background
Adult Philadelphia (Ph)-negative B‑acute lymphoblastic leukemia (Ph-ALL) patients often exhibit elevated levels of CRLF2 expression, which is associated with poor clinical outcome.
Aim
To identify CRLF2 rearrangement in Ph-negative ALL patients and assess its prognostic significance.
Methods
The fluorescence in situ hybridization (FISH) technique was used to correlate the clinical outcome of 84 patients with Ph-ALL with a CRLF2 rearrangement from the hematology unit.
Results
This study included 84 newly diagnosed ALL patients. Based on their CRLF2 rearrangement status, the patients were divided into two groups: (CRLF2+) positive patients, comprising 17.9% of the total (n = 15), and (CRLF2−) negative patients, accounting for 82.1% (n = 69). In CRLF2+ patients, the median initial total leucocytic count (TLC) was 14.9 × 103 (range 4.8–486.0) vs. 6.9 × 103 (range 0.1–586.0) in CRLF2− patients (P = 0.005). Based on a median follow-up period of 333 days (range 36–730), the CRLF2+ group had shorter overall survival compared to the CRLF2− group (250 vs 730 days, P < 0.001). After a median follow-up of 198 days, the CRLF2+ group had a significantly lower disease-free survival compared to the CRLF2− group (184 vs 525 days, P < 0.001).
Conclusion
CRLF2 expression was associated with poor clinical outcomes among ALL patients.